Forte Biosciences, Inc. (NASDAQ:FBRX – Get Free Report) saw a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 12,500 shares, a drop of 55.8% from the February 13th total of 28,300 shares. Based on an average daily volume of 50,900 shares, the short-interest ratio is currently 0.2 days. Approximately 0.2% of the company’s shares are sold short.
Analyst Ratings Changes
A number of brokerages have recently commented on FBRX. TD Cowen began coverage on shares of Forte Biosciences in a research note on Tuesday, January 21st. They issued a “buy” rating on the stock. Chardan Capital reissued a “buy” rating and issued a $64.00 target price on shares of Forte Biosciences in a research note on Wednesday, December 4th.
View Our Latest Research Report on Forte Biosciences
Institutional Inflows and Outflows
Forte Biosciences Price Performance
Forte Biosciences stock traded down $0.20 during midday trading on Friday, hitting $5.80. 39,207 shares of the stock were exchanged, compared to its average volume of 146,898. Forte Biosciences has a 1 year low of $4.11 and a 1 year high of $28.68. The firm has a market cap of $37.08 million, a P/E ratio of -0.36 and a beta of 2.35. The company has a 50 day moving average price of $12.50 and a two-hundred day moving average price of $11.53.
Forte Biosciences Company Profile
Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.
Read More
- Five stocks we like better than Forte Biosciences
- What Are Dividend Champions? How to Invest in the Champions
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Dividend Capture Strategy: What You Need to Know
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Forte Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forte Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.